This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

S. M. DRANCE, M.B., F.R.C.S. (Eng.)

AMA Arch Ophthalmol. 1959;62(4):679-684.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The carbonic anhydrase inhibitors, particularly acetazolamide (Diamox), have become a standard adjunct in the short-term management of the glaucomas since they were first evaluated by Becker,¹ in 1954. There are now numerous reports in the literature which indicate that long-term therapy is effective with these compounds without any obvious ill effect on the ocular tissues. The greatest number of failures in long-term control of the glaucomas with carbonic anhydrase inhibitors to date have been due to the large proportion of sideeffects which have frequently necessitated cessation of therapy; only relatively few cases have become truly refractory. A number of newer carbonic anhydrase inhibitors are being evaluated in a search for a more powerful inhibitor with minimal side-effects in the dosage required.

Ethoxzolamide (Cardrase) is a new potent carbonic anhydrase inhibitor the use of which in ophthalmology has been reported on, particularly in the therapy of intraocular inflammation, by Gordon, . . . [Full Text PDF of this Article]

Author Affiliations
Saskatoon, Sask., Canada

From the Glaucoma Clinic, University Hospital, University of Saskatchewan.

Footnotes
Submitted for publication Feb. 4, 1959.

Cardrase supplied by The Upjohn Company, Kalamazoo, Mich., who also supported the investigation with a grant.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?